The Community Forum creates a space for the PHUSE Community to unite and discuss industry topics of interest in an informal setting. Alongside this, each Working Group will use Disqus to host offline discussions and continue sharing information. This event is free and takes place virtually. If you have any questions, contact workinggroups@phuse.global. To catch up on previous Community Forums, visit the PHUSE Community Forum Archive. |
Upcoming Community Forums:
| Date/ Time | Working Group | Title | Speakers |
|---|---|---|---|
18 January 14:00–15:00 (GMT) 09:00–10:00 (EST) | Real World Evidence | Dr Cheryl Grandinetti, FDA and Kris Wenzel, MMS Holdings |
Previous Community Forums:
Click on links below for more information to view the recordings.
| Date (2023) | Working Group | Title | Speakers | Recordings |
|---|---|---|---|---|
| 18 January | Emerging Trends & Technologies | Submitting Real-world Data | Parag Shiralkar, Sumptuous Data Sciences & Jeff Abolafia, Pinnacle 21 | |
| 16 February | Safety Analytics | Reimagining a Safety Submission – Aggregate Safety Assessment Planning | Greg Ball, ASAPprocess, Mary Nilsson, Eli Lilly, Mac Gordon, Janssen Research & Development & Barbara Hendrickson, University of Chicago | |
21 February | Data Transparency | Data Privacy and Data Sharing in Clinical Trials | Devaki Thavarajah, Instem & Deborah Collyar, Founder and President, PAIR | |
27 March | Safety Analytics | Reimagining a Safety Submission – Vision of Interactive Safety Reviews | Greg Ball, ASAPprocess, Mary Nilsson, Eli Lilly, Wei Wang, Eli Lilly, Xiangyun Wang, Genentech, Raj Kiran, Takeda, Melvin Munsaka, Abbvie, Neetu Sangari, Pfizer, Jeremy Wildfire, Gilead, Khushboo Sharma, Accumulus & Bill Gibson, Accumulus | |
12 April | Emerging Trends & Technologies | RWD/RWE Programming & Reporting Standards: Utilising OMOP Standards | Berber Snoeijer, ClinLine, Mary Anne Rutkowski, Merck & Co, Jerry Wang, Janssen Research and Development & Mike Briganti, Janssen Research & Development | |
6 July | Real World Evidence | Designing Your RWD Study: Is Your Data Fit for Purpose? | Andy Richardson Zenetar, Elizabeth Merrall, Janssen Research and Development, Jonathan Assayag, Pfizer & Mary Anne Rutkowski, Merck | |
5 October | Real World Evidence | Experiences with Adapting RWD into CDISC Submission Standards | Lauren Green, Amgen, Jeffrey Abolafia, Pinnacle 21, Christine Rossin, Pfizer & Sandra VanPelt Nguyen, Pfizer | Recording |